Could Novavax Become the Next Moderna?

Novavax entered the coronavirus vaccine market late, missing out on the biggest revenue opportunity. This disappointed investors, and the stock plummeted more than 90% from its high. But recent news -- a big partnership with pharmaceutical giant Sanofi -- and Novavax's progress with newer vaccine candidates signal brighter days may be ahead. Could Novavax carve out share in the vaccine market and potentially become the next Moderna? Let's find out. Novavax's $1.2 billion deal Last week, Novavax announced a ...